Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Open accessPublished version of a preprint
Abstract
The off-target distribution of anticancer nanoparticles to fibroblasts creates a barrier to the effective treatment of desmoplastic tumors. However, we hypothesized that this nanoparticle detriment might be exploited to target the expression of secreted cytotoxic proteins from tumor-associated fibroblasts (TAF) as an anticancer strategy. In addressing this hypothesis, plasmids encoding the secretable TNF-related factor sTRAIL were loaded into lipid-coated protamine DNA complexes and administered by infusion in a murine xenograft model of human desmoplastic bladder carcinoma. Three doses were sufficient to generate approximately 70% of TAFs as sTRAIL-producing cells. sTRAIL triggered apoptosis in tumor cell nests adjacent to TAFs. Furthermore, it reverted residual fibroblasts to a quiescent state due to insufficient activation, further compromising tumor growth and remodeling the microenvironment to favor second-wave nanotherapy. We confirmed the efficacy of this strategy in an orthotopic xenograft model of human pancreatic cancer, where the desmoplastic stroma is well known to be a major barrier to the delivery of therapeutic nanoparticles. Collectively, our results offer a proof of concept for the use of nanoparticles to modify TAFs as an effective strategy to treat desmoplastic cancers. Cancer Res; 77(3); 719–31. ©2016 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Use of nanoparticles to modify CAFs can be an effective strategy to treat desmoplastic cancers.
“Thus the use of NP to modify CAFs can be an effective strategy to treat desmoplastic cancers (Fig. 2b) [83].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [83]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 3× · see citing works
“Secondly, the reduction of the fibrotic content, which decompresses the intratumoral vasculature, creates a window for the second-wave nanotherapy (9,34).”
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · see citing works
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · see citing works
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194 · see citing works
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · see citing works
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,678 · see citing works
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,516 · see citing works
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158 · see citing works
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101 · see citing works
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079 · see citing works
Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
Cirri, P., & Chiarugi, P. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9340-x · Cited by 515 · see citing works
Tumour‐associated macrophages act as a slow‐release reservoir of nano‐therapeutic Pt(IV) pro‐drug
Miller, M. A., Zheng, Y.-R., Gadde, S., Pfirschke, C., Zope, H., Engblom, C., Kohler, R. H., Iwamoto, Y., Yang, K. S., Askevold, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms9692 · Cited by 441 · see citing works
Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy
Meijer, T. W. H., Kaanders, J. H. A. M., Span, P. N., & Bussink, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0858 · Cited by 433 · see citing works
Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410 · see citing works
(1999) · PubMed · Cited by 348 · see citing works
Kim, S. M., Lim, J. Y., Park, S., Jeong, C. H., Oh, J. H., Jeong, M., Oh, W., Park, S., Sung, Y., & Jeun, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0451 · Cited by 277 · see citing works
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors
Miao, L., Lin, C. M., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.017 · Cited by 264 · see citing works
Self-citationInteraction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts
Hawinkels, L. J. A. C., Paauwe, M., Verspaget, H. W., Wiercinska, E., Zon, J. M. V. D., van der Ploeg, K., Koelink, P. J., Lindeman, J. H. N., Mesker, W. E., ten Dijke, P., et al. (2012) · Oncogene · doi:10.1038/onc.2012.536 · Cited by 257 · see citing works
Size Effects on Diffusion Processes within Agarose Gels
Fatin‐Rouge, N., Starchev, K., & Buffle, J. (2004) · Biophysical Journal · doi:10.1016/s0006-3495(04)74325-8 · Cited by 248 · see citing works
Chono, S., Li, S., Conwell, C. C., & Huang, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.006 · Cited by 237 · see citing works
Self-citationWang, Y., Xu, Z., Guo, S., Zhang, L., Sharma, A. K., Robertson, G. P., & Huang, L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.135 · Cited by 191 · see citing works
Self-citationMeng, H., Zhao, Y., Dong, J. I., Xue, M., Lin, Y., Ji, Z., Mai, W. X., Zhang, H., Chang, C. H., Brinker, C. J., et al. (2013) · ACS Nano · doi:10.1021/nn404083m · Cited by 191 · see citing works
Miao, L., Guo, S., Zhang, J., Kim, W. Y., & Huang, L. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201401076 · Cited by 178 · see citing works
Self-citationZhang, X., Dong, Y., Zeng, X., Liang, X., Li, X., Wei, T., Chen, H., Jiang, Y., Mei, L., & Feng, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.034 · Cited by 175 · see citing works
Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin
LeBeau, A. M., Brennen, W. N., Aggarwal, S., & Denmeade, S. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1170 · Cited by 159 · see citing works
Incio, J., Suboj, P., Chin, S. M., Vardam-Kaur, T., Liu, H., Hato, T., Babykutty, S., Chen, I. X., Deshpande, V., Jain, R. K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141392 · Cited by 142 · see citing works
Guo, S., Wang, Y., Miao, L., Xu, Z., Lin, C. M., Zhang, Y., & Huang, L. (2013) · ACS Nano · doi:10.1021/nn403606m · Cited by 141 · see citing works
Self-citationTumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Smith, N. R., Baker, D., Farren, M. R., Pommier, A., Swann, R., Wang, X., Mistry, S., McDaid, K., Kendrew, J., Womack, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1637 · Cited by 136 · see citing works
Ernsting, M. J., Hoang, B., Lohse, I., Undzys, E., Cao, P. M., Do, T., Gill, B., Pintilie, M., Hedley, D. W., & Li, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.023 · Cited by 133 · see citing works
Murakami, M., Ernsting, M. J., Undzys, E., Holwell, N., Foltz, W. D., & Li, S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0062 · Cited by 129 · see citing works
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin
Miao, L., Wang, Y., Lin, C. M., Xiong, Y., Chen, N., Zhang, L., Kim, W. Y., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.027 · Cited by 119 · see citing works
Self-citationDuisit, G., Saleün, S., Douthe, S., Barsoum, J., Chadeuf, G., & Moullier, P. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199903/04)1:2 · Cited by 117 · see citing works
Voortman, J., Resende, T. P., Hassan, M., Giaccone, G., & Kruyt, F. A. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0167 · Cited by 116 · see citing works
Zhang, J., Miao, L., Guo, S., Zhang, Y., Zhang, L., Satterlee, A., Kim, W. Y., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.016 · Cited by 110 · see citing works
Self-citationThe Expression of Exogenous Genes in Macrophages: Obstacles and Opportunities
Zhang, X., Edwards, J. P., & Mosser, D. M. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-396-7_9 · Cited by 90 · see citing works
Inducible Release of TRAIL Fusion Proteins from a Proapoptotic Form for Tumor Therapy
Shah, K., Tung, C., Yang, K. S., Weissleder, R., & Breakefield, X. O. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3516 · Cited by 87 · see citing works
FAP-1 in pancreatic cancer cells
Ungefroren, H., Kruse, M., Trauzold, A., Roeschmann, S., Röder, C., Arlt, A., Henne‐Bruns, D., & Kalthoff, H. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.15.2735 · Cited by 79 · see citing works
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Hingtgen, S., Ren, X., Terwilliger, E., Classon, M., Weissleder, R., & Shah, K. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0640 · Cited by 79 · see citing works
Matsuzaki, H., Schmied, B. M., Ulrich, A. B., Standop, J., Schneider, M. B., Batra, S. K., Picha, K. S., & Pour, P. M. (2001) · PubMed · Cited by 67 · see citing works
Islam, S. S., Mokhtari, R. B., Hout, Y. E., Azadi, M. A., Alauddin, M., Yeger, H., & Farhat, W. A. (2013) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-013-0216-4 · Cited by 66 · see citing works
O’Leary, L., van der Sloot, A. M., Reis, C. R., Deegan, S., Ryan, A. E., Dhami, S. P. S., Murillo, L. S., Cool, R. H., de Sampaio, P. C., Thompson, K., et al. (2015) · Oncogene · doi:10.1038/onc.2015.180 · Cited by 61 · see citing works
TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells
Cantarella, G., Risuglia, N., Dell’Eva, R., Lempereur, L., Albini, A., Pennisi, G., Scoto, G. M., Noonan, D. M., & Bernardini, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603092 · Cited by 60 · see citing works
Self-Organization of Polarized Cell Signaling via Autocrine Circuits: Computational Model Analysis
Maly, I. V., Wiley, H. S., & Lauffenburger, D. A. (2004) · Biophysical Journal · doi:10.1016/s0006-3495(04)74079-5 · Cited by 57 · see citing works
Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics
Vlieghere, E. D., Verset, L., Demetter, P., Bracke, M., & de Wever, O. (2015) · Virchows Archiv · doi:10.1007/s00428-015-1818-4 · Cited by 50 · see citing works
Roode, L. E., Brighton, H. E., Bo, T., Perry, J. L., Parrott, M. C., Kersey, F. R., Luft, J. C., Bear, J. E., DeSimone, J. M., & Davis, I. J. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.382 · Cited by 34 · see citing works
Dasargyri, A., Hervella, P., Christiansen, A. J., Proulx, S. T., Detmar, M. J., & Leroux, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.021 · Cited by 29 · see citing works
Novak, M., Leonard, M. K., Yang, X. H., Kowluru, A., Belkin, A. M., & Kaetzel, D. M. (2015) · Experimental Dermatology · doi:10.1111/exd.12697 · Cited by 24 · see citing works
Yoo, J., Choi, S., Hwang, K., Cho, W., Jung, C., Kwon, S., & Im, D. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.832 · Cited by 20 · see citing works
Zhu, Y., Yin, W., Ba, Y., TIAN, L., Gu, Z., Zhang, M., & Zhong, C. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1020 · Cited by 12 · see citing works
Self-citationKimura, J., Ono, H. A., Kosaka, T., Nagashima, Y., Hirai, S., Ohno, S., Aoki, K., Julia, D., Yamamoto, M., Kunisaki, C., et al. (2013) · Cancer Science · doi:10.1111/cas.12196 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [23]Shah K Tung CH Yang K Weissleder R Breakefield XO Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy Cancer research 2004 64 9 3236 3242 doi 15126365
Cited by
Sorted by citations
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,884 · see citing works
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · see citing works
“2b) [83] .”
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Narayanan, J., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,116 · see citing works
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773 · see citing works
Self-citationFibrosis and cancer: A strained relationship
Piersma, B., Hayward, M.-K., & Weaver, V. M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188356 · Cited by 686 · see citing works
Fiori, M. E., Franco, S. D., Villanova, L., Bianca, P., Stassi, G., & Maria, R. D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 648 · see citing works
Fibroblasts in cancer: Unity in heterogeneity
Chhabra, Y., & Weeraratna, A. T. (2023) · Cell · doi:10.1016/j.cell.2023.03.016 · Cited by 488 · see citing works
Overchuk, M., & Zheng, G. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383 · see citing works
Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies
Liu, M., Abad, B. L. D. J., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.021 · Cited by 353 · see citing works
Han, X., Li, Y., Xu, Y., Zhao, X., Zhang, Y., Yang, X., Wang, Y., Zhao, R., Anderson, G. J., Zhao, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05906-x · Cited by 339 · see citing works
Self-citationPhuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 304 · see citing works
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 284 · see citing works
Self-citationHuang, K., Hsu, F., Qiu, J. T., Chern, G., Lee, Y.-A., Chang, C., Huang, Y., Sung, Y., Chiang, C.-C., Huang, R.-L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax5032 · Cited by 258 · see citing works
Self-citationNanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256 · see citing works
He, J., Li, C., Ding, L., Huang, Y., Yin, X., Zhang, J., Zhang, J., Yao, C., Liang, M., Pirraco, R. P., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902409 · Cited by 248 · see citing works
Self-citationNanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy
Musetti, S., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b05893 · Cited by 239 · see citing works
Self-citationCancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 252 · see citing works
Recent advances in active targeting of nanomaterials for anticancer drug delivery
Dutta, B., Barick, K. C., & Hassan, P. A. (2021) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2021.102509 · Cited by 236 · see citing works
Hyperthermia and smart drug delivery systems for solid tumor therapy
Seynhaeve, A. L. B., Amin, M., Haemmerich, D., van Rhoon, G. C., & ten Hagen, T. L. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.004 · Cited by 235 · see citing works
Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics
Chen, Q., Liu, G., Liu, S., Su, H., Wang, Y., Li, J., & Luo, C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.009 · Cited by 228 · see citing works
Self-citationZhou, Y., Chen, X., Cao, J., & Gao, H. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00649a · Cited by 213 · see citing works
Cancer-associated fibroblasts—heroes or villains?
Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0509-3 · Cited by 212 · see citing works
Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P. B., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 201 · see citing works
Applications and challenges of ultra-small particle size nanoparticles in tumor therapy
Xu, J., Song, M., Zhou, F., Zheng, L., Huang, X., & Liu, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.028 · Cited by 186 · see citing works
Liu, Q., Chen, F., Hou, L., Shen, L., Zhang, X., Wang, D., & Huang, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b01890 · Cited by 182 · see citing works
Self-citationNanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178 · see citing works
Self-citationDesign of nanocarriers based on complex biological barriers in vivo for tumor therapy
Liu, J., Li, M., Luo, Z. Y., Dai, L., Guo, X., & Cai, K. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.010 · Cited by 157 · see citing works
Hou, L., Chen, D., Wang, R., Wang, R., Zhang, H., Zhang, Z., Nie, Z., & Lu, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202014397 · Cited by 143 · see citing works
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140 · see citing works
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 138 · see citing works
Self-citationShen, L., Li, J., Liu, Q., Song, W., Zhang, X., Tiruthani, K., Hu, H., Das, M., Goodwin, T. J., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00967 · Cited by 138 · see citing works
Self-citationMartin, J. D., Panagi, M., Wang, C., Khan, T., Martin, M. R., Voutouri, C., Toh, K., Papageorgis, P., Mpekris, F., Polydorou, C., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b07865 · Cited by 137 · see citing works
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer
Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., Goodwin, T. J., Dorosheva, O., Liu, R., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01786 · Cited by 131 · see citing works
Self-citationChan, T., Shaked, Y., & Tsai, K. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00688 · Cited by 121 · see citing works
Yu, Q., Qiu, Y., Li, J., Tang, X., Wang, X., Cun, X., Xu, S., Liu, Y., Li, M., Zhang, Z., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.040 · Cited by 119 · see citing works
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 117 · see citing works
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118 · see citing works
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
Gowd, V., Ahmad, A., Tarique, M., Suhail, M., Zughaibi, T. A., Tabrez, S. S. M., & Khan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.026 · Cited by 115 · see citing works
Ni, K., Xu, Z., Culbert, A. A., Luo, T., Guo, N., Yang, K., Pearson, E. A., Preusser, B., Wu, T., Rivière, P. J. L., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00846-w · Cited by 113 · see citing works
Feng, J., Xu, M., Wang, J., Zhou, S., Liu, Y., Liu, S., Huang, Y., Chen, Y., Liang, C., Song, Q., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119907 · Cited by 107 · see citing works
Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines
Li, M., Zhang, Y., Zhang, Q., & Li, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100364 · Cited by 105 · see citing works
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Jing, Z., Du, Q., Zhang, X., & Zhang, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137147 · Cited by 104 · see citing works
Liu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 103 · see citing works
Das, M., Shen, L., Liu, Q., Goodwin, T. J., & Huang, L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.012 · Cited by 96 · see citing works
Self-citationNanoparticles mediated tumor microenvironment modulation: current advances and applications
Raju, G. S. R., Pavitra, E., Varaprasad, G. L., Bandaru, S. S., Nagaraju, G. P., Farran, B., Huh, Y. S., & Han, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01476-9 · Cited by 101 · see citing works
Truffi, M., Mazzucchelli, S., Bonizzi, A., Sorrentino, L., Allevi, R., Vanna, R., Morasso, C., & Corsi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061263 · Cited by 92 · see citing works
Hou, L., Liu, Q., Shen, L., Liu, Y., Zhang, X., Chen, F., & Huang, L. (2018) · Theranostics · doi:10.7150/thno.24821 · Cited by 90 · see citing works
Self-citationPei, Y., Liang, C., Huang, Y., Wang, J., Feng, J., Xu, M., Chen, Y., Song, Q., Jiang, G., Gu, X. Q., et al. (2019) · Small · doi:10.1002/smll.201900631 · Cited by 90 · see citing works
Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
Sun, B., Hyun, H., Li, L., & Wang, A. Z. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0424-4 · Cited by 91 · see citing works
Guo, J. X., Zeng, H., & Chen, Y. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00014 · Cited by 90 · see citing works
Yu, Q., Tang, X., Zhao, W., Qiu, Y., He, J., Wan, D., Li, J., Wang, X., He, X., Liu, Y., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.002 · Cited by 85 · see citing works
Liu, Q., Zhu, H., Tiruthani, K., Shen, L., Chen, F., Gao, K., Zhang, X., Hou, L., Wang, D., Liu, R., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07384 · Cited by 83 · see citing works
Self-citationLiu, Y., Tiruthani, K., Wang, M., Zhou, X., Qiu, N., Xiong, Y., Pecot, C. V., Liu, R., & Huang, L. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00588f · Cited by 81 · see citing works
Self-citationDrug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy
Liu, M., Song, W., & Huang, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.032 · Cited by 81 · see citing works
Self-citationmRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 80 · see citing works
Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors
Chen, Y., Song, W., Shen, L., Qiu, N., Hu, M., Liu, Y., Liu, Q., & Huang, L. (2019) · ACS Nano · doi:10.1021/acsnano.8b07830 · Cited by 79 · see citing works
Self-citationApplication of nanotechnology in the diagnosis and treatment of bladder cancer
Xu, Y., Luo, C., Wang, J., Chen, L., Chen, J., Chen, T., & Zeng, Q. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01104-y · Cited by 78 · see citing works
Self-citationLiu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 77 · see citing works
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 77 · see citing works
Complex interplay between tumor microenvironment and cancer therapy
Shen, M., & Kang, Y. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0663-7 · Cited by 76 · see citing works
Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 78 · see citing works
Stromal reprogramming: A target for tumor therapy
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117049 · Cited by 74 · see citing works
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
Spano, C., Grisendi, G., Golinelli, G., Rossignoli, F., Prapa, M., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., Miselli, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37433-6 · Cited by 74 · see citing works
Amini, M. A., Abbasi, A. Z., Cai, P., Lip, H., Gordijo, C. R., Li, J., Chen, B., Zhang, L., Rauth, A. M., & Wu, X. Y. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy131 · Cited by 70 · see citing works
Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Raaijmakers, K., Adema, G. J., Bussink, J., & Ansems, M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03251-0 · Cited by 71 · see citing works
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71 · see citing works
TRAIL-based gene delivery and therapeutic strategies
Zhong, H., Wang, H., Li, J., & Huang, Y. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0287-8 · Cited by 70 · see citing works
TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies
Dianat‐Moghadam, H., Heidarifard, M., Mahari, A., Shahgolzari, M., Keshavarz, M., Nouri, M., & Amoozgar, Z. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104716 · Cited by 69 · see citing works
Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance
Zhao, Z., Li, T., Sun, L. L., Yuan, Y., & Zhu, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115425 · Cited by 68 · see citing works
Hameed, S., Chen, H., Irfan, M. I., Bajwa, S. Z., Khan, W. S., Baig, S. M., & Dai, Z. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00812 · Cited by 65 · see citing works
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 65 · see citing works
Mortezaee, K. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117145 · Cited by 63 · see citing works
Multifunctional nanostructures: Intelligent design to overcome biological barriers
Azizi, M., Jahanban‐Esfahlan, R., Samadian, H., Hamidi, M., Seidi, K., Dolatshahi‐Pirouz, A., Ahmadieh-Yazdi, A., Shavandi, A., Laurent, S., Hagh, M. B. O., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100672 · Cited by 63 · see citing works
Yu, S., Wang, S., Wang, X., & Xu, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03518-8 · Cited by 65 · see citing works
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y.-H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 51 · see citing works
BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma
Liu, Q., Zhu, H., Liu, Y., Musetti, S., & Huang, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2079-7 · Cited by 62 · see citing works
Self-citationNanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer
Liu, Y., Qiu, N., Shen, L., Liu, Q., Zhang, J., Cheng, Y., Lee, K., & Huang, L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.040 · Cited by 61 · see citing works
Self-citationStrategies targeting tumor immune and stromal microenvironment and their clinical relevance
Hu, M., & Huang, L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114137 · Cited by 58 · see citing works
Self-citationFor and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy
Karimi, S., Bakhshali, R., Bolandi, S., Zahed, Z., Zadeh, S. S. M., Zenjanab, M. K., & Jahanban‐Esfahlan, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101626 · Cited by 60 · see citing works
Greene, M. K., Johnston, M. C., & Scott, C. J. (2021) · Cancers · doi:10.3390/cancers13246175 · Cited by 56 · see citing works
Tanaka, H., Sakurai, Y., Anindita, J., & Akita, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.001 · Cited by 56 · see citing works
TRAIL–NP hybrids for cancer therapy: a review
Belkahla, H., Herlem, G., Picaud, F., Gharbi, T., Hémadi, M., Ammar, S., & Micheau, O. (2017) · Nanoscale · doi:10.1039/c7nr01469d · Cited by 52 · see citing works
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
Caster, J. M., Callaghan, C. M., Seyedin, S. N., Henderson, K., Sun, B., & Wang, A. Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.009 · Cited by 55 · see citing works
Responsive and activable nanomedicines for remodeling the tumor microenvironment
Zhang, Y., Han, X., & Nie, G. (2020) · Nature Protocols · doi:10.1038/s41596-020-00421-0 · Cited by 52 · see citing works
Extracellular citrate and metabolic adaptations of cancer cells
Parkinson, E. K., Adamski, J., Zahn, G., Gaumann, A. K. A., Flores‐Borja, F., Ziegler, C. M., & Mycielska, M. E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10007-1 · Cited by 49 · see citing works
Huang, H., Sung, Y., Li, C., Wan, D., Chao, P., Tseng, Y., Liao, B.-W., Cheng, H., Hsu, F., Huang, C., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325180 · Cited by 51 · see citing works
Liu, C., Chern, G., Hsu, F., Huang, K., Sung, Y., Huang, H., Qiu, J.-T. T., Wang, S., Lin, C., Wu, C., et al. (2017) · Hepatology · doi:10.1002/hep.29513 · Cited by 51 · see citing works
Self-citationChen, X., Yu, Q., Liu, Y., Sheng, Q., Shi, K., Wang, Y., Li, M., Zhang, Z., & He, Q. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.09.003 · Cited by 51 · see citing works
Self-citationNanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy
Wu, X., Wang, S., Li, M., Wang, A., Zhou, Y. Y., Li, P., & Wang, Y. (2017) · Nanoscale · doi:10.1039/c7nr04959e · Cited by 50 · see citing works
Self-citationNormalization in tumor ecosystem: Opportunities and challenges
Mortezaee, K. (2021) · Cell Biology International · doi:10.1002/cbin.11655 · Cited by 49 · see citing works
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine
Cassani, M., Fernandes, S., Pagliari, S., Cavalieri, F., Caruso, F., & Forte, G. (2024) · Advanced Science · doi:10.1002/advs.202409898 · Cited by 49 · see citing works
Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues
Elwakeel, E., & Weigert, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111636 · Cited by 48 · see citing works
Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
Sakurai, Y., Abe, N., Yoshikawa, K., Oyama, R., Ogasawara, S., Murata, T., Nakai, Y., Tange, K., Tanaka, H., & Akita, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.052 · Cited by 46 · see citing works
Li, W., Little, N., Park, J., Foster, C. A., Chen, J., & Lu, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00455 · Cited by 46 · see citing works
Dana, P., Thumrongsiri, N., Tanyapanyachon, P., Chonniyom, W., Punnakitikashem, P., & Saengkrit, N. (2022) · Nanomaterials · doi:10.3390/nano13010107 · Cited by 44 · see citing works
Recent advances in drug delivery and targeting for the treatment of pancreatic cancer
Pramanik, N., Gupta, A. K., Ghanwatkar, Y., & Mahato, R. I. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.053 · Cited by 42 · see citing works
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 43 · see citing works
Drug Delivery Strategies for the Treatment of Pancreatic Cancer
Olajubutu, O., Ogundipe, O. D., Adebayo, A. S., & Adesina, S. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051318 · Cited by 42 · see citing works
Liu, X., Zhou, J., Wu, H., Chen, S., Zhang, L., Tang, W., Duan, L., Wang, Y., McCabe, E., Hu, M., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.012 · Cited by 41 · see citing works
Self-citationPolymer-Mediated Penetration-Independent Cancer Therapy
Ding, J., Feng, X., Jiang, Z., Xu, W., Guo, H., Zhuang, X., & Chen, X. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b01263 · Cited by 41 · see citing works
- Authors
- Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Shenyang Pharmaceutical University (CN)
- China Pharmaceutical University (CN)
- Corresponding author
- Huang, Leaf
- ORCID
- Venue
- Cancer Research
- Published
- 2017-01-31
- Volume
- 77
- Issue
- 3
- Pages
- 719-731
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC5290135
- OpenAlex
- W2555883270
- Cited by
- 215
- References
- 50
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 16 · 2023: 16 · 2022: 26 · 2021: 29 · 2020: 31 · 2019: 31 · 2018: 21 · 2017: 16
- FWCI
- 9.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- NIH (CA149363, CA151652, and CA149387)
- North Carolina Biotech Center Institutional (2005-IDG-1016)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Keywords
- cancer-associated fibroblasts, desmoplastic tumors, tumor microenvironment, lipid-coated nanoparticles, pancreatic cancer, nanoparticle delivery
- MeSH terms
- Cancer-Associated Fibroblasts, Animals, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Flow Cytometry, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Neoplasms, Experimental, Pancreatic Neoplasms, Blotting, Western, Polymerase Chain Reaction, Apoptosis, Xenograft Model Antitumor Assays, NIH 3T3 Cells, Cell Line, Tumor, Mice, TNF-Related Apoptosis-Inducing Ligand, Nanoconjugates, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
